Search

Your search keyword '"Girard, N."' showing total 2,218 results

Search Constraints

Start Over You searched for: Author "Girard, N." Remove constraint Author: "Girard, N."
2,218 results on '"Girard, N."'

Search Results

1. Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project

3. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

6. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

7. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

14. Caractéristiques cliniques et séquences thérapeutiques des patients atteints de cancer bronchique non à petites cellules (CBNPC) métastatique avec mutation KRAS G12C traités par sotorasib dans l’ATUc

15. Caractéristiques et prise en charge des patients porteurs de mutations complexes de l’EGFR dans les cancers bronchiques non à petites cellules : étude multicentrique rétrospective

16. Traitement des cancers bronchiques à petites cellules (CBPC) : intérêt des études en vie réelle. À propos de 2 études de l’IFCT : IFCT-1905 Clinatezo et IFCT-2105 Lurbiclin

17. 115TiP MDT-BRIDGE: A phase II study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC

19. 70P LIST (Lung Initiative on Sequence Therapy): A real-world study of nivolumab for advanced NSCLC in France - First effectiveness, safety, and IO-rechallenge results

22. Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial

24. Recommandations de l’Intergroupe francophone de cancérologie thoracique, de la Société de pneumologie de langue française, et de la Société d’imagerie thoracique sur le dépistage du cancer bronchopulmonaire par tomodensitométrie à faible dose d’irradiation

26. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

28. MA08.04 Assessment of the Quality of the Surgical Procedure and the Operative Report Based on Nationwide French Registry: A RYTHMIC study

29. OA17.03 Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC (PACIFIC-R)

30. P2.09-29 Efficacy of Osimertinib (OSI) vs 1st-Generation TKI Followed by OSI by Clinical Profile in EGFR-Mutant NSCLC (SMILE STUDY)

32. P1.28-09 Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel

33. VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC

35. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

40. CTA contributions to the 33rd International Cosmic Ray Conference (ICRC2013)

47. The combination of baseline magnetic resonance perfusion-weighted imaging-derived tissue volume with severely prolonged arterial-tissue delay and diffusion-weighted imaging lesion volume is predictive of MCA-M1 recanalization in patients treated with endovascular thrombectomy.

48. The combination of baseline magnetic resonance perfusion-weighted imaging-derived tissue volume with severely prolonged arterial-tissue delay and diffusion-weighted imaging lesion volume is predictive of MCA-M1 recanalization in patients treated with endovascular thrombectomy.

Catalog

Books, media, physical & digital resources